Biological modifiers (etetrinate and interferon alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 1, 1996, Pages 21-24

  Avilés, Agustin ^a   Guzmán, Renaldo ^a   García, Edna L ^a   Díaz Maqueo, José C ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Cutaneous T cell lymphoma; Etetrinate; Interferon; Malignant lymphoma

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ETRETINATE; BIOLOGICAL RESPONSE MODIFIER;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; DRY SKIN; INFLUENZA; LEUKOPENIA; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETRETINATE; FEMALE; HUMANS; INTERFERON ALFA-2A; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED;

EID: 0029893049     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.21     Document Type: Article

References (11)

1. Bradther LR, McFadden N Successful treatment of mycosis fungoides with the combination of etetrinate and human recombinant interferon alfa 2a. J Dermatol Treat 1989;1:29-32.
2. Kuzel TM, Roening HH, Rossen ST. Mycosis fungoides and the Sézary syndrome. A review of pathogenesis, diagnosis and therapy. J Clin Oncol 1991;9:1298-1313
3. Zackhein HS. Treatment of cutaneous T-cell lymphoma. Sem Dermatol 1994;13:207-215.
4. Jones GW Mycosis fungoides. Issues and management 1995. Cancer J 1994;7:214-219.
5. Bunn PA, Noms DA. The therapeutic role of interferon. and monoclonal antibodies in cutaneous T cell lymphoma. J Invest Dermatol 1990;95(Suppl) 209S-212 S.
6. Thestrup-Pedersen K, Hammer R, Kaltoff K et al. Treatment of mycosis fungoides with recombinant interferon alfa 2a alone and in combination with etetrinate. Br J Dermatol 1988;118:811-818.
7. Préno B, Claudy A, Meynadier J et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon alfa 2a and etetrinate. Br J Dermatol 1991;125:456-459.
8. Zacharie H, Thestrup-Pedersen K. Interferon alpha and etetrinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990,95(Suppl) 206 S-208 S.
9. Vondenheid EC, Diamond LW, van Volten WA et al. Lymph node classification system in cutaneous T-cell lymphoma. Cancer 1994;73:207-218.
10. Avilés A, Diaz-Maqueo JC, García EL et al Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Invest New Drugs 1992;10:351-355.
11. Avilés A, Duque G, Tlavera A, Guzmán R. Interferon alfa 2b as maintenance therapy in low-grade malignant lymphoma improves duration of remission and survival. Leuk Lymph 1995 (in press).